Combined oral contraceptives and treatment of new coronavirus infection (COVID-19): aspects of drug interactions

2021 ◽  
Vol 19 (1) ◽  
pp. 149-158
Author(s):  
O.A. Limanova ◽  
◽  
L.E. Fedotova ◽  
O.A. Gromova ◽  
◽  
...  
Keyword(s):  
Drug Interactions ◽  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Antihypertensive Drugs ◽  
Efficacy And Safety ◽  
Antiinflammatory Drugs ◽  
Combined Oral Contraceptives ◽  
Chlormadinone Acetate ◽  
Coronavirus Infection ◽  
Oral Hypoglycemic Drugs

This article discusses the problem of drug interactions between combined oral contraceptives on the example of Belara® (30 μg of ethinyl estradiol + 2 mg of chlormadinone acetate; Gedeon Richter, Hungary) and medications recommended for the treatment of new coronavirus infection (COVID-19) and concomitant disorders at the pharmacodynamic and pharmacokinetic levels with an assessment of the efficacy and safety of therapy for females. We described safe, potentially dangerous, and dangerous combinations of these drugs. Key words: new coronavirus infection (CAVID-19), combined oral contraceptives, antiviral drugs, antibacterial drugs, antiinflammatory drugs, anticoagulants, migraine drugs, antihypertensive drugs, oral hypoglycemic drugs, essential micronutrients, pharmacodynamic and pharmacokinetic interactions

scholarly journals Combined oral contraception and treatment of new coronavirus infection (COVID-19): drug interaction issues

2021 ◽  
pp. 30-39
Author(s):  
O. A. Limanova ◽  
O. A. Gromova ◽  
L. E. Fedotova
Keyword(s):  
Drug Interaction ◽  
Oral Contraceptives ◽  
Female Body ◽  
Oral Contraception ◽  
Combined Oral Contraceptives ◽  
Coronavirus Infection

Combined oral contraception and treatment of new coronavirus infection (COVID-19): issues of drug interaction This article examines the interaction of combined oral contraceptives with drugs recommended in the treatment of new coronavirus infection (COVID-19) at the pharmacodynamic and pharmacokinetic levels, with an assessment of the effectiveness and safety of therapy for the female body.

More Contraindications to the Pill

PEDIATRICS ◽  
1980 ◽  
Vol 66 (4) ◽  
pp. 644-645
Author(s):  
Janet P. Realini
Keyword(s):  
Oral Contraceptives ◽  
Animal Studies ◽  
Ethinyl Estradiol ◽  
Combined Oral Contraceptives ◽  
Excellent Review ◽  
Ovulation Inhibition ◽  
Relative Potencies

I read with interest the excellent review by Drs Greydanus and McAnarney.1 Several of their points concerning combined oral contraceptives deserve discussion, however. The relative potencies of the progestins and estrogens contained in oral contraceptives are controversial. Progestin potency is difficult to measure reliably, and comparisons among progestins can be misleading.2 While animal studies have suggested that mestranol is a weaker estrogen than ethinyl estradiol, a study of human ovulation inhibition suggested that ethinyl estradiol may be weaker than mestranol.3

Estradiol Valerate/Dienogest: A Novel Oral Contraceptive

2011 ◽  
Vol 45 (10) ◽  
pp. 1256-1261 ◽  
Author(s):  
Karen L Whalen ◽  
Renee Rose
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Data Extraction ◽  
Estradiol Valerate ◽  
Efficacy And Safety ◽  
Data Synthesis ◽  
Efficacy Trials ◽  
Study Selection ◽  
Pearl Index

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the new oral contraceptive estradiol valerate/dienogest. Data Sources: Searches of PubMed (1966-July 2011) and International Pharmaceutical Abstracts (1970-July 2011) were conducted using the key words estradiol valerate, dienogest, Natazia, and Olaira. Bibliographies of retrieved articles were reviewed to identify additional références. Study Selection and Data Extraction: All identified studies published in English and involving efficacy and safety of estradiol valerate/dienogest as an oral contraceptive were reviewed. Data Synthesis: Estradiol valerate/dienogest is a 4-phasic oral contraceptive approved for the prevention of pregnancy. The 4-phasic design allows for acceptable cycle control with this hormonal combination. In efficacy trials of estradiol valerate/dienogest in women aged 18–35 years, the Pearl Index ranged from 0.40 to 1.64, a range comparable to that of other combination oral contraceptives. The safety profile was also similar to that of other oral contraceptives, with headache, metrorrhagia, breast tenderness, nausea or vomiting, acne, and weight gain reported as the most common adverse effects. Menstrual bleeding patterns and cycle control with estradiol valerate/dienogest were comparable to those of a monophasic oral contraceptive containing ethinyl estradiol/levonorgestrel. Estradiol valerate/dienogest differs from other oral contraceptives in that il necessitates more stringent dosing guidelines for maximum contraceptive efficacy. New starts should be on the first day of menses only, and a back-up method of contraception is required for the first 9 days, as compared to 7 days with other oral contraceptives. Back-up contraception is usually required for any pill taken more than 12 hours later than scheduled. Conclusions: Estradiol valerate/dienogest is an effective oral contraceptive. Because it has more stringent start times and requires a longer duration of back-up contraception and stricter adherence, estradiol valerate/dienogest should be reserved for patients who are intolerant of other combination oral contraceptives.

Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea

2015 ◽  
Vol 31 (10) ◽  
pp. 774-778 ◽  
Author(s):  
Giovanni Grandi ◽  
Antonella Napolitano ◽  
Anjeza Xholli ◽  
Alessandra Tirelli ◽  
Costantino Di Carlo ◽  
...  
Keyword(s):  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Primary Dysmenorrhea ◽  
Chlormadinone Acetate ◽  
Nomegestrol Acetate

scholarly journals Hormonal effects of drosperinone and ethinyl estradiol based combined oral contraceptives on polycystic ovarian syndrome

2021 ◽  
Vol 10 (5) ◽  
pp. 1824
Author(s):  
Madhusmita S. Nayak ◽  
Deepa D. Kala ◽  
Amit Agarwal
Keyword(s):  
Oral Contraceptives ◽  
Polycystic Ovarian Syndrome ◽  
Ethinyl Estradiol ◽  
Effective Means ◽  
Free Testosterone ◽  
Sex Hormone Binding Globulin ◽  
Combined Oral Contraceptives ◽  
Serum Luteinizing Hormone ◽  
Hospital Patients ◽  
Ovarian Syndrome

Background: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder treated with combined oral contraceptives (COCs). The androgenic potential of any type of COC is in part determined by the progestin present. A newer form of progestin, drospirenone, has been recently introduced, and is available in combination with ethinyl estradiol.Methods: The study was conducted on 60 patients fulfilling inclusion criteria, in the department of obstetrics and gynecology, Terna Medical College and Hospital. Patients were diagnosed as PCOS according to Rotterdam criteria. After initial evaluation, blood samples were sent for levels of serum luteinizing hormone (LH), follicle stimulating hormone (FSH), dehydroepiandrosterone-sulphate (DHEA-S), free testosterone, sex hormone binding globulin (SHBG). Each patient was advised to take a combination of EE (30 mcg) + drosperinone (3 mg), 1 tablet daily from the second day of her menstruation for 21 days then a 7 days gap and again for 21 days and so on cyclically for 3 cycles, then to repeat the tests as done at the beginning.  Hirsutism was assessed clinically using the Ferriman-Gallwey scale at initial visit and three months later.Results: We found a significant improvement in the Serum LH, FSH levels and a significant fall in free testosterone levels accompanied by a rise in SHBG levels. There is also overall improvement in the hirsutism scores.Conclusions: Drosperinone based COCs are a good and effective means of treatment of PCOS. Treatment duration of three months was found to be effective in our study.

scholarly journals Treatment of premenstrual dysphoric disorders with combined oral contraceptives

2019 ◽  
Vol 2 (14) ◽  
pp. 23-26
Author(s):  
K. B. Loginova ◽  
G. M. Dyukova ◽  
Yu. V. Dobrokhotova ◽  
A. B. Danilov
Keyword(s):  
Emotional Disorders ◽  
Oral Contraceptives ◽  
Premenstrual Syndrome ◽  
Sleep Disturbances ◽  
Ethinyl Estradiol ◽  
Physical Symptoms ◽  
Severe Form ◽  
Reproductive Period ◽  
Emotional Symptoms ◽  
Combined Oral Contraceptives

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS) with severe psycho-emotional disorders. The frequency of occurrence of PMDD in women of the reproductive period of the Russian Federation is estimated at an average of 15.6 %. The development of PMDD is based on the individual sensitivity of neurotransmitters and neuropeptides to fluctuations in the levels of sex steroid hormones of the ovulatory menstrual cycle, therefore, hormone therapy drugs are used for PMDD therapy — combined oral contraceptives (COC) that suppress ovulation.The purpose of this study was to evaluate the effectiveness of COC containing drospirenone in the treatment of PMDD.Materials and methods. 78 women of the reproductive period underwent a comprehensive examination and treatment of PMDD symptoms with contraceptives containing 30 mg of ethinyl estradiol and 3 mg of drospirenone (Midian).Results of the study. The age of patients with PMDD averaged 33.7 years; 55 % of women were between 25–34 years old; 97 % needed contraception; all women represented in the group had higher education, normal menstrual function and body mass index. After 3 months of treatment, there was a statistically significant decrease in pain of various localization, problems with appetite, difficulties in communicating with others, sleep disturbances, and an increase in productivity at work, at home and in school. After 6 months of treatment, COC psycho-emotional symptoms, such as depression, anger, irritation, emotional lability, anxiety, tension, loss of control, significantly regressed, while the effectiveness of therapy reached 50 % relative to the original background. Physical symptoms of PMS, such as swelling of the mammary glands, pain of various locations, sleep disturbances, were stopped on average by 70 %.Conclusions. COC containing drospirenone can be used to treat severe premenstrual syndrome, i. e. PMDD.

Sign in / Sign up

Export Citation Format

Share Document